Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet
, Roser Pinyol
, Mark Yarchoan
, Amit G. Singal
,
Thomas U. Marron
,
Myron Schwartz
, Eli Pikarsky
, Masatoshi Kudo
, Richard S. Finn
Cancer Clinical Investigation
Icahn School of Medicine at Mount Sinai
Liver Cancer
Medicine
Medicine - Liver Diseases
Mount Sinai Tisch Cancer Center
Human Immune Monitoring Center
Marc and Jennifer Lipschultz Precision Immunology Institute
Medicine - Hematology and Medical Oncology
Recanati Miller Transplantation Institute
Surgery
Research output
:
Contribution to journal
›
Review article
›
peer-review
249
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hepatocellular Carcinoma
100%
Adjuvant Immunotherapy
100%
Neoadjuvant Immunotherapy
100%
Resection
75%
Immune Checkpoint Inhibitors
75%
Local Ablation
75%
Neoadjuvant
50%
Liver Transplantation
25%
Adjuvant Therapy
25%
Clinical Trials
25%
High Risk
25%
Mechanism of Action
25%
Systemic Therapy
25%
Clinical Trial Design
25%
Cancer Mortality
25%
Curative Treatment
25%
Randomized Clinical Trial
25%
Tumor Immune Microenvironment
25%
Liver Cancer
25%
Relapse Risk
25%
Unmet Needs
25%
Patient's Will
25%
Cancer Causes
25%
Recurrence-free Survival
25%
Common Cancers
25%
Survival Benefit
25%
Advanced Hepatocellular Carcinoma
25%
Recurrent Disease
25%
Median Overall Survival
25%
Survival Duration
25%
Cancer Vaccine
25%
Design Considerations
25%
Atezolizumab Plus Bevacizumab
25%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Neoadjuvant Immunotherapy
100%
Immune Checkpoint Inhibitor
60%
Diseases
40%
Liver Transplantation
20%
Recurrent Disease
20%
Malignant Neoplasm
20%
Adjuvant Therapy
20%
Clinical Trial
20%
Biological Marker
20%
Tumor Immune Microenvironment
20%
Overall Survival
20%
Cancer Mortality
20%
Recurrence Free Survival
20%
Liver Cancer
20%
Systemic Therapy
20%
Clinical Trial Design
20%
Bevacizumab
20%
Atezolizumab
20%
Tumor Vaccine
20%
Randomized Clinical Trials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Immunotherapy
100%
Immune Checkpoint Inhibitor
60%
Diseases
40%
Malignant Neoplasm
20%
Biological Marker
20%
Clinical Trial
20%
Overall Survival
20%
Recurrent Disease
20%
Cancer Mortality
20%
Recurrence Free Survival
20%
Randomized Clinical Trial
20%
Liver Cancer
20%
Bevacizumab
20%
Clinical Trial Design
20%
Atezolizumab
20%
Tumor Vaccine
20%